Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

735 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Joint action of miR-126 and MAPK/PI3K inhibitors against metastatic melanoma.
Pedini F, De Luca G, Felicetti F, Puglisi R, Boe A, Arasi MB, Fratini F, Mattia G, Spada M, Caporali S, Biffoni M, Giuliani A, Carè A, Felli N. Pedini F, et al. Among authors: spada m. Mol Oncol. 2019 Sep;13(9):1836-1854. doi: 10.1002/1878-0261.12506. Epub 2019 Aug 6. Mol Oncol. 2019. PMID: 31115969 Free PMC article.
IFN-α potentiates the direct and immune-mediated antitumor effects of epigenetic drugs on both metastatic and stem cells of colorectal cancer.
Buoncervello M, Romagnoli G, Buccarelli M, Fragale A, Toschi E, Parlato S, Lucchetti D, Macchia D, Spada M, Canini I, Sanchez M, Falchi M, Musella M, Biffoni M, Belardelli F, Capone I, Sgambato A, Vitiani LR, Gabriele L. Buoncervello M, et al. Among authors: spada m. Oncotarget. 2016 May 3;7(18):26361-73. doi: 10.18632/oncotarget.8379. Oncotarget. 2016. PMID: 27028869 Free PMC article.
New derivatives of the antimalarial drug Pyrimethamine in the control of melanoma tumor growth: an in vitro and in vivo study.
Tommasino C, Gambardella L, Buoncervello M, Griffin RJ, Golding BT, Alberton M, Macchia D, Spada M, Cerbelli B, d'Amati G, Malorni W, Gabriele L, Giammarioli AM. Tommasino C, et al. Among authors: spada m. J Exp Clin Cancer Res. 2016 Sep 6;35(1):137. doi: 10.1186/s13046-016-0409-9. J Exp Clin Cancer Res. 2016. PMID: 27599543 Free PMC article.
Combining Type I Interferons and 5-Aza-2'-Deoxycitidine to Improve Anti-Tumor Response against Melanoma.
Lucarini V, Buccione C, Ziccheddu G, Peschiaroli F, Sestili P, Puglisi R, Mattia G, Zanetti C, Parolini I, Bracci L, Macchia I, Rossi A, D'Urso MT, Macchia D, Spada M, De Ninno A, Gerardino A, Mozetic P, Trombetta M, Rainer A, Businaro L, Schiavoni G, Mattei F. Lucarini V, et al. Among authors: spada m. J Invest Dermatol. 2017 Jan;137(1):159-169. doi: 10.1016/j.jid.2016.08.024. Epub 2016 Sep 10. J Invest Dermatol. 2017. PMID: 27623509 Free article.
A new bioavailable fenretinide formulation with antiproliferative, antimetabolic, and cytotoxic effects on solid tumors.
Orienti I, Francescangeli F, De Angelis ML, Fecchi K, Bongiorno-Borbone L, Signore M, Peschiaroli A, Boe A, Bruselles A, Costantino A, Eramo A, Salvati V, Sette G, Contavalli P, Zolla L, Oki T, Kitamura T, Spada M, Giuliani A, Baiocchi M, La Torre F, Melino G, Tartaglia M, De Maria R, Zeuner A. Orienti I, et al. Among authors: spada m. Cell Death Dis. 2019 Jul 23;10(7):529. doi: 10.1038/s41419-019-1775-y. Cell Death Dis. 2019. PMID: 31332161 Free PMC article.
An organoid model of colorectal circulating tumor cells with stem cell features, hybrid EMT state and distinctive therapy response profile.
De Angelis ML, Francescangeli F, Nicolazzo C, Signore M, Giuliani A, Colace L, Boe A, Magri V, Baiocchi M, Ciardi A, Scarola F, Spada M, La Torre F, Gazzaniga P, Biffoni M, De Maria R, Zeuner A. De Angelis ML, et al. Among authors: spada m. J Exp Clin Cancer Res. 2022 Mar 8;41(1):86. doi: 10.1186/s13046-022-02263-y. J Exp Clin Cancer Res. 2022. PMID: 35260172 Free PMC article.
Type I IFNs promote cancer cell stemness by triggering the epigenetic regulator KDM1B.
Musella M, Guarracino A, Manduca N, Galassi C, Ruggiero E, Potenza A, Maccafeo E, Manic G, Mattiello L, Soliman Abdel Rehim S, Signore M, Pietrosanto M, Helmer-Citterich M, Pallocca M, Fanciulli M, Bruno T, De Nicola F, Corleone G, Di Benedetto A, Ercolani C, Pescarmona E, Pizzuti L, Guidi F, Sperati F, Vitale S, Macchia D, Spada M, Schiavoni G, Mattei F, De Ninno A, Businaro L, Lucarini V, Bracci L, Aricò E, Ziccheddu G, Facchiano F, Rossi S, Sanchez M, Boe A, Biffoni M, De Maria R, Vitale I, Sistigu A. Musella M, et al. Among authors: spada m. Nat Immunol. 2022 Sep;23(9):1379-1392. doi: 10.1038/s41590-022-01290-3. Epub 2022 Aug 24. Nat Immunol. 2022. PMID: 36002648 Free PMC article.
MiR126-targeted-nanoparticles combined with PI3K/AKT inhibitor as a new strategy to overcome melanoma resistance.
Arasi MB, De Luca G, Chronopoulou L, Pedini F, Petrucci E, Flego M, Stringaro A, Colone M, Pasquini L, Spada M, Lulli V, Perrotta MC, Calin GA, Palocci C, Biffoni M, Felicetti F, Felli N. Arasi MB, et al. Among authors: spada m. Mol Ther. 2024 Jan 3;32(1):152-167. doi: 10.1016/j.ymthe.2023.11.021. Epub 2023 Nov 21. Mol Ther. 2024. PMID: 37990493 Free article.
735 results